AA
MTNB icon

ALPS Advisors’s Matinas BioPharma MTNB Stock Holding History

ALPS Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,812
Closed -$120K – 868
2017
Q3 		$120K Buy
1,812
+162
+10% +$10.8K ﹤0.01% 763
2017
Q2 		$139K Buy
+1,650
New +$222K ﹤0.01% 757

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ALPS Advisors's MTNB Position: Q4 2017 in Review

ALPS Advisors sold out of Matinas BioPharma (MTNB) in Q4 2017, closing a stake of 1,812 shares — an estimated $120K sold.

ALPS Advisors first reported a position in MTNB in Q2 2017 and held it in 2 quarters. The position peaked at $139K in Q2 2017. 49 funds tracked by Wall St. Rank hold MTNB as of Q4 2017.

  • ALPS Advisors reported no remaining Matinas BioPharma position as of Q4 2017 after selling out during the quarter.
  • ALPS Advisors sold 1,812 Matinas BioPharma shares in Q4 2017, an estimated $120K.
  • ALPS Advisors first reported a position in Matinas BioPharma in Q2 2017 and held it in 2 quarters.
  • ALPS Advisors's Matinas BioPharma position peaked at $139K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.